Podcast Episodes
Back to Search
Episode 296: ASCO GU 2024: Novel approaches to QOL and belzutifan
Season 2 Episode 296
Cris Bergerot describes her modifications of existing QOL models while Tom describes the QOL data from LS005
2 years, 9 months ago
Episode 295: ASCO GU 2024: Adjuvant Therapy in Renal Cancer
Season 2 Episode 295
Pedro Barata summarises his ASCO GU discussion on this topic.
2 years, 9 months ago
Episode 294: ASCO GU 2024: Adjuvant Pembrolizumab in Bladder Cancer
Season 2 Episode 294
Andrea Apolo describes the results of this positive trial.
2 years, 9 months ago
Episode 293: ASCO GU 2024: BRCAaway and CONTACT2
Season 2 Episode 293
Kim Chi discussed the prostate cancer oral session at ASCO GU 2024.
2 years, 9 months ago
Episode 292: ASCO GU 2024: HPN328 - A Tri-Specific T Cell Engager in Prostate Cancer
Season 2 Episode 292
Misha Beltran describes the activity of this novel agent in neuroendocrine prostate cancer.
2 years, 9 months ago
Episode 291: ASCO GU 2024: CONTACT2 - Cabozantinib and Atezolizumab in Prostate Cancer
Season 2 Episode 291
Neeraj Agarwal describes the results of this positive randomised Phase 3 trial.
2 years, 9 months ago
Episode 290: ASCO GU 2024 Preview
Season 2 Episode 290
What to look out for in bladder, prostate and renal cancer at this year's meeting.
2 years, 9 months ago
Episode 289: The Uromigos Paper of the Month - TALAPRO2 in Nature Medicine
Season 2 Episode 288
Karim Fizazi discusses the clinical and biomarker components of this data.
2 years, 9 months ago
Episode 288: APCCC #3: Controversies around Radiotherapy
Season 2 Episode 289
Thomas Zilli discusses controversies around radiotherapy in prostate cancer.
2 years, 9 months ago
Episode 287 APCCC: Early Discontinuation of Therapy in HSPC
Season 2 Episode 287
Silke Gillessen and Betrand Tombal discuss the questions which will address this issue in Lugano in March 2024.
2 years, 9 months ago